There is vociferous outrage against McDonald’s right now for pegging the price of a Big Mac meal at $18, never mind the caveat that the skewed pricing pertained to a single outlet out of the thousands on the continental US. Yet, even if we assume that this fast food inflationary trend is aggressive and widespread, it is certainly not sustainable, as highlighted by the fact that a veritable Wall Street titan now expects global annual sales of GLP-1 anti-obesity drugs to reach a whopping $130 billion by 2030. “It frustrates and worries me when I hear about an $18 Big […]
Read full article at https://wccftech.com/130-billion-in-annual-sales-of-glp-1-anti-obesity-drugs-by-2030/
